Zachary Katz

Zachary Katz

Auto-generated profile, based on publicly available information

Zachary Katz

Fdn Innovat New Diagnost FIND, Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
JNJOSEPH NDUNG'U
JOSEPH NDUNG'U
ABAlain Boulangé
Alain Boulangé
APAlbert Picado
Albert Picado
AMAlbert Mugenyi
Albert Mugenyi
AMAllan Mortensen
Allan Mortensen
ZKZachary Katz
Zachary Katz

31 January 2022 in African Journal of Laboratory Medicine
Verified
Journal Article
Open access
ATAndré Trollip
André Trollip
RGRenuka Gadde
Renuka Gadde
TDTjeerd Datema
Tjeerd Datema
KGKamau Gatwechi
Kamau Gatwechi
LOLinda Oskam
Linda Oskam
HAHeidi Albert
Heidi Albert
Background: In low-resource settings, antimicrobial resistance (AMR) is detected by traditional culture-based methods and ensuring the quality of such services is a challenge. The AMR Scorecard provides laboratories with a technical assessment tool for strengthening the quality of bacterial culture, identification, and antimicrobial testing procedures.Objective: To evaluate the performance of the AMR Scorecard in 11 pilot laboratory evaluations in three countries also assessed with the Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) checklist.Methods: Pilot laboratory evaluations were conducted in Cameroon, Ethiopia and Kenya between February 2019 and March 2019. Assessors with previous SLIPTA and microbiology experience were trained. Assessors performed the laboratory assessments using the SLIPTA and AMR Scorecard tools.Results: Weaknesses in technical procedures and the quality management systems were identified in all areas and all laboratories. Safety had the highest mean performance score (SLIPTA: 68%; AMR Scorecard: 73%) while management review had the lowest (SLIPTA: 32%; AMR Scorecard: 8%) across all laboratories. The AMR Scorecard scores were generally consistent with SLIPTA scores. The AMR Scorecard identified technical weaknesses in AMR testing, and SLIPTA identified weaknesses in the quality management systems in the laboratories.Conclusion: Since the AMR Scorecard identified important gaps in AMR testing not detected by SLIPTA, it is recommended that microbiology laboratories use SLIPTA and the AMR Scorecard in parallel when preparing for accreditation. Expanding the use of the AMR Scorecard is a priority to address the need for quality clinical microbiology laboratory services in support of optimal patient care and AMR surveillance.